Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

Cancer Science
Hirotsugu Kenmotsu, Yusuke Tanigawara

Abstract

Docetaxel (Taxotere(®)) has been one of the most important chemotherapeutic drugs for cancer treatment since 1996. Although a large number of clinical studies have been conducted in various cancer fields, there is a discrepancy in the standard dose between Japan and Western countries. This article reviews the pharmacokinetic, pharmacodynamic and toxicological profiles of docetaxel, and explains why there exists an ethnic difference in dose, and further discusses which direction we should go forward to solve this problem. The original recommended dose was 100 mg/m(2) every 3 weeks in US and European populations, while a Japanese phase I study suggested the recommended dose as 60 mg/m(2) every 3 weeks. A prospective population pharmacokinetic analysis of docetaxel conducted in both the USA/Europe and Japan, indicated an absence of ethnic difference in the pharmacokinetics. Both analyses demonstrated that docetaxel clearance is related to α1-acid glycoprotein level, hepatic function, age and body surface area. The relationship was observed between increasing docetaxel dose and increased tumor response rates across the dose range of 60 to 100 mg/m(2). The area under the serum concentration time curve (AUC) of docetaxel at the first...Continue Reading

References

Feb 20, 1991·Journal of the National Cancer Institute·I Ringel, S B Horwitz
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H BurrisG Rodriguez
Oct 1, 1993·Pharmacology·P de Witte
Jul 1, 1996·Biopharmaceutics & Drug Disposition·N NagaiH Ogata
Apr 1, 1996·Journal of Pharmacokinetics and Biopharmaceutics·R BrunoL B Sheiner
Jan 1, 1996·Investigational New Drugs·S UrienJ P Tillement
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R BrunoL B Sheiner
Jul 8, 1998·Cancer Chemotherapy and Pharmacology·H L McLeodR Bruno
Mar 27, 1999·Clinical Pharmacokinetics·S J Clarke, L P Rivory
Feb 9, 2000·Cancer Chemotherapy and Pharmacology·H RosingJ H Beijnen
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N YamamotoN Saijo
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W C ZamboniK H Tkaczuk
Feb 17, 2001·Clinical Pharmacology and Therapeutics·C Veyrat-FolletP Chaikin
May 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L van ZuylenJ Verweij
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boon-Cher GohHow-Sung Lee
Jan 3, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C H SmorenburgA Sparreboom
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L R MitchellM Green
Oct 10, 2003·Clinical Pharmacology and Therapeutics·Walter J LoosAlex Sparreboom
Mar 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharyn D BakerMichael A Carducci
Apr 28, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A RudekS D Baker
Apr 30, 2004·Clinical Pharmacology and Therapeutics·Frederike K EngelsAlex Sparreboom
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hironobu MinamiHiroyasu Ogata
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 8, 2005·Clinical Pharmacology and Therapeutics·Sharyn D BakerAlex Sparreboom
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert J ten TijeSharyn D Baker
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E JonesP M Ravdin
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang SchuetteMonika Serke
Dec 24, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CampsUNKNOWN Spanish Lung Cancer Group
Mar 3, 2006·Clinical Pharmacokinetics·Sharyn D BakerJaap Verweij
Mar 18, 2006·Cancer Science·Hironobu MinamiHirofumi Fujii
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rodryg RamlauFrances A Shepherd
Jun 13, 2006·Clinical Pharmacology and Therapeutics·A TranJ M Tréluyer
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tessa M BoschJan H M Schellens
Oct 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vernon HarveySoeren Cold
Feb 24, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Dorte WintherAnders Bonde Jensen
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lionel D LewisUNKNOWN Cancer and Leukemia Group B
Jun 28, 2007·British Journal of Cancer·F PuissetE Chatelut

❮ Previous
Next ❯

Citations

Jun 9, 2016·South Asian Journal of Cancer·Vanita NoronhaKumar Prabhash
Jun 3, 2016·Asia-Pacific Journal of Clinical Oncology·Natasha WoodwardCaroline Ryan
Feb 27, 2016·CA: a Cancer Journal for Clinicians·Giuseppe CuriglianoCarlo Maria Cipolla
Sep 24, 2016·Expert Review of Respiratory Medicine·A MatikasA Kotsakis
Apr 28, 2018·Critical Reviews in Analytical Chemistry·Gilmar Hanck da SilvaMarlus Chorilli
Nov 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hideaki TakahashiToshitaka Nagao
Nov 19, 2019·Drug Delivery·Ketevan PaliashviliRichard M Day
Apr 25, 2020·Japanese Journal of Clinical Oncology·Kohei ShitaraToshihiko Doi
Nov 27, 2019·Prostate Cancer and Prostatic Diseases·Claudia KeschMartin E Gleave
Jan 5, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ayako UenoShiro Imai
Apr 28, 2017·Breast Cancer Research and Treatment·Yu LiuYong Huang
May 10, 2017·Molecular Carcinogenesis·Yangang ZhangJianping Xie
Jun 24, 2017·British Journal of Clinical Pharmacology·Hirotsugu KenmotsuYusuke Tanigawara
Sep 8, 2018·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Soha TalimaNeemat Kassem
Sep 27, 2019·Experimental and Therapeutic Medicine·Mai HazekawaManabu Nakashima
May 28, 2020·Journal of Hematology & Oncology·Yue YangLufeng Zheng
Nov 30, 2019·Journal of Clinical Pharmacy and Therapeutics·Weihua RenLiang Guo
Oct 19, 2020·Clinical Journal of Gastroenterology·Kunihiro TsujiHisashi Doyama
Dec 11, 2020·Cancers·Xingjian Zhai, Yassine El Hiani
Jan 12, 2021·Bulletin du cancer·Sonia Ben NasrAbderrazek Haddaoui
Jun 27, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Florence AtrafiPatrick Schöffski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.